Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced that it will present a poster with new data on the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the 7th Asian Oncology Summit being held from April 10-12, 2015 in Shanghai, China.

The poster will be presented by Dr. Jeremy Simpson, Vice President, Clinical Development at Bionomics, and is entitled, A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC): Results of the randomized phase II DisrupTOR-1 trial. The Poster Walk session is during the Welcome Reception on Friday, April 10th, 2015 at 5:45 p.m. CST in the Mandarin Hall of the Oriental Riverside Hotel and Convention Centre .

The data identify ferritin and IL-8 as two baseline biomarkers that correlate with an improved progression free survival (PFS) in patients. Eighty nine percent of patients expressing higher plasma levels of ferritin and lower plasma levels of IL-8 at baseline were disease progression-free at six months. The data show that biomarker-based patient selection has the potential to optimise clinical outcomes in the treatment of renal cancer. There are 6.3 new cases of renal cancer and 1.7 deaths per 100,000 people in Asia each year.

BNC105 is a novel compound being developed as a vascular disrupting agent (VDA) for the treatment of cancer. VDAs are drugs that disrupt the blood vessels that nourish tumours. This approach has a number of advantages over classical chemotherapy, including stronger impact on tumour cell death, applicability to a wider variety of cancers, and lowered risk of the emergence of therapy-resistant tumour cells.

SOURCE Bionomics Limited


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Cleveland Clinic’s ROBIN center may pave way for more effective radiation, immunotherapy treatments